Lymphoma Clinical Trial
Official title:
Phase I Study of CDDO in Solid Tumors and Lymphomas
Background:
- CDDO is a novel synthetic triterpenoid which is a potent multifunctional molecule. It
induces apoptosis in vitro in malignant cells through both intrinsic and extrinsic
pathways, and it controls cellular differentiation, apoptosis, and growth inhibition by
serving as a ligand for the transcription factor peroxisome proliferator activator
receptor-gamma (PPAR gamma).
- Based on in vitro activity, it holds considerable promise as a novel anti-tumor agent
against a wide range of malignancies by concurrently targeting multiple pathways leading
to oncogenesis.
- In vivo data demonstrates that the drug is well tolerated in dogs, and has anti-tumor
effects, dependent upon dose schedule.
Objectives:
Primary:
- To determine the dose limiting toxicities, toxicity profile, and maximum tolerated dose
of CDDO when administered in adult patients with solid tumors and lymphomas.
- To characterize the pharmacokinetics of CDDO.
Secondary:
- To obtain preliminary evidence of anti-tumor activity of CDDO in this population.
- To evaluate the in vivo molecular and biological effects of CDDO by assessing changes in
biomarkers of apoptosis and cell cycle arrest.
Eligibility:
- Patients with advance, histological-confirmed malignancies refractory to standard
therapy or for which no standard therapy exist.
- Patients should have adequate liver, renal and bone marrow function.
Study Design:
- Accordingly with the accelerated titration design 4B, dose levels will initially be
increased at 100% increments, and one new patient per dose level will be treated per
4-week course.
- The accelerated phase ends when one patient experiences DLT during any course of
treatment or when two different patients experience grade 2 toxicity during first course
of treatment.
- When the first instance of grade 2 toxicity is observed two additional patients must
have been treated at that dose, or a higher dose, (during any course) without
experiencing moderate or worse toxicity, in order that the accelerated phase continue.
- When the accelerated phase ends, dose-escalation will revert to a more conservative
modified Fibonacci scheme with 40% dose-step increments, with at least 3 patients
treated per dose level.
Background:
- CDDO is a novel synthetic triterpenoid which is a potent multifunctional molecule. It
induces apoptosis in vitro in malignant cells through both intrinsic and extrinsic
pathways, and it controls cellular differentiation, apoptosis, and growth inhibition by
serving as a ligand for the transcription factor peroxisome proliferator activator
receptor-gamma (PPAR gamma).
- Based on in vitro activity, it holds considerable promise as a novel anti-tumor agent
against a wide range of malignancies by concurrently targeting multiple pathways leading
to oncogenesis.
- In vivo data demonstrates that the drug is well tolerated in dogs, and has anti-tumor
effects, dependent upon dose schedule.
Objectives:
Primary:
- To determine the dose limiting toxicities, toxicity profile, and maximum tolerated dose
of CDDO when administered in adult patients with solid tumors and lymphomas.
- To characterize the pharmacokinetics of CDDO.
Secondary:
- To obtain preliminary evidence of anti-tumor activity of CDDO in this population.
- To evaluate the in vivo molecular and biological effects of CDDO by assessing changes in
biomarkers of apoptosis and cell cycle arrest.
Eligibility:
- Patients with advance, histological-confirmed malignancies refractory to standard
therapy or for which no standard therapy exist.
- Patients should have adequate liver, renal and bone marrow function.
Study Design:
- Accordingly with the accelerated titration design 4B, dose levels will initially be
increased at 100% increments, and one new patient per dose level will be treated per
4-week course.
- The accelerated phase ends when one patient experiences DLT during any course of
treatment or when two different patients experience grade 2 toxicity during first course
of treatment.
- When the first instance of grade 2 toxicity is observed two additional patients must
have been treated at that dose, or a higher dose, (during any course) without
experiencing moderate or worse toxicity, in order that the accelerated phase continue.
- When the accelerated phase ends, dose-escalation will revert to a more conservative
modified Fibonacci scheme with 40% dose-step increments, with at least 3 patients
treated per dose level.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |